Abbreviations & Acronyms BMI = body mass index CI = confidence interval CT = computed tomography GIST = gastrointestinal stromal tumor HR = hazard ratio KPS = Karnofsky Performance Status mRCC = metastatic renal cell carcinoma MSKCC = Memorial Sloan Kettering Cancer Center mTOR = mammalian target of rapamycin OS = overall survival PD-1/PD-L1 = programmed death-1/programmed death-ligand 1 PD = progressive disease PFS = progression-free survival PR = partial remission PSA = prostate-specific antigen RCC = renal cell carcinoma RECIST = Response Evaluation Criteria in Solid Tumors SD = stable disease SPP = survival post-progression TGR = tumor growth rate TGV = tumor growth velocity TGV1 = tumor growth velocity before drug withdrawal TGV2 = tumor growth velocity after drug withdrawal TKI = tyrosine kinase inhibitor VEGF-TKI = vascular endothelial growth factor tyrosine kinase inhibitor Objectives: To investigate the role of tumor growth velocity in defining tumor progression in metastatic renal cell carcinoma patients treated with the vascular endothelial growth factor tyrosine kinase inhibitor, sorafenib. Methods: A modified calculation for tumor growth velocity was introduced to evaluate the tumor growth velocity, before and after sorafenib withdrawal. Known prognostic factors together with tumor growth velocity before drug withdrawal and tumor growth velocity after drug withdrawal were compared using a v 2 -test from a contingency table, and partial likelihood test from a Cox regression model for overall survival. Results: A total of 114 patients who reached progressive disease and withdrew from sorafenib were enrolled after a median follow-up period of 107.8 months. Tumor growth velocity before drug withdrawal was 7.347 AE 4.040, and tumor growth velocity after drug withdrawal was 11.647 AE 5.937 (P < 0.001). Higher tumor growth velocity before drug withdrawal was correlated with a higher risk Memorial Sloan Kettering Cancer Center score (P = 0.022), Karnofsky Performance Status <80 (P = 0.028), non-clear cell carcinoma (P = 0.037), higher tumor nucleus grade (P < 0.001) and best treatment response (P < 0.001). Patients with tumor growth velocity before drug withdrawal >5.0 had shorter overall survival (P < 0.001). On multivariate analysis, factors associated with overall survival were high/intermediate Memorial Sloan Kettering Cancer Center risk score (hazard ratio 2.119, P = 0.006), non-clear histological subtype (hazard ratio 1.900, P = 0.031), tumor growth velocity before drug withdrawal ≥5.0 (hazard ratio 2.758, P < 0.001) and progressive disease as best response (hazard ratio 2.069, P = 0.001). Conclusions: Significantly faster tumor growth can be observed if sorafenib is discontinued in the case of disease progression. Thus, we suggest not to withdraw targeted agents until tumor growth velocity is >5.0.
Introduction
The RECIST, which is the present standard of care for defining tumor response and progression to therapy, and to determine when to switch therapy or add another agent, were established in 1999. 1, 2 However, an increasing number of clinical findings have shown that RECIST-based assessment does not fully characterize the response and progression in patients treated with targeted therapies. 3, 4 These drugs, especially VEGF-TKI, lead to reduced density and perfusion in solid tumors and induce tumor shrinkage, which is significantly associated with OS. 5, 6 Several novel radiographic response criteria have been investigated, such as the Choi criteria for GIST involving CT density, 7 and immune-related response criteria considering tumor burden for all immunotherapy-treated malignancies. 8 These issues should also be taken into account for mRCC treated by VEGF-TKIs. RCC is the third most common malignancy of the genitourinary system, accounting for approximately 3% of all adult malignancies and 2% of all cancer deaths. 9 For decades, the outcome for patients with metastatic disease was dismal, and the 5-year OS rate was <10%. 10 The introduction of novel VEGF-TKIs, such as sorafenib, sunitinib, pazopanib, axitinib, cabozantinib and lenvatinib, has dramatically changed the treatment strategies for mRCC. 11 However, long-lasting SD is more common than objective response under VEGF-TKI therapy, and RECIST cannot interpret the overall efficacy of VEGF-TKI agents very well, especially in those with long-lasting SD after treatment. 12, 13 The TGR can dynamically reflect tumor volume change within a specific time throughout treatments, allowing for a real-time evaluation of tumor response. 14, 15 Nevertheless, the calculation of TGR is relatively complex, and it is not easy to carry out this method for individual patients in clinical practice. The present study introduces TGV as an alternative to TGR, and evaluates its role in the assessment of tumor progression for mRCC patients treated with sorafenib. To our knowledge, this is the first report of the role of TGV in re-evaluating the efficacy of VEGF-TKI and defining tumor progression in mRCC patients.
Methods Patients
Between April 2006 and April 2011, a total of 152 patients with mRCC were treated by sorafenib as a second-line therapy after failing cytokine treatment in the Department of Urology of Fudan University Shanghai Cancer Center (Shanghai, China). All the consecutive and non-selected patients were treated and followed up according to an institutional treatment protocol developed by our institution. To the last follow-up date (31 December 2017), 150 patients reached progressive disease after a median follow-up time of 23.0 months (4.0-140.0 months). The other two patients died without progression. A total of 36 patients were excluded from the present study (two only had bone lesions, and another 34 had dosage escalation of sorafenib after PD and did not withdraw VEGF-TKI therapy). All the included 114 patients had baseline CT scans available that showed at least one measurable metastatic lesion (≥10 mm in greatest diameter), and follow-up CT scans were carried out every 2-3 months during treatment, and the first 1 month (washout period) after failing sorafenib treatment assessed by RECIST. 16 None of the patients initiated additional treatment during the washout period. All CT scans were independently reviewed by senior radiologists. Patients provided informed consent, and their records were retrospectively reviewed with institutional review board approval by the ethics committee of Fudan University Shanghai Cancer Center.
Definition of TGV

Traditional calculation of TGR
According to the method of Fert e et al., tumor size (D) was defined as the longest diameter of the target lesion. 17 Let t be the time expressed in months at tumor evaluation. Assuming the tumor growth follows an exponential law, V t (the tumor volume at time t) is equal to V t = V 0 exp(TG.t), where V 0 is volume at baseline and TG is the growth rate. They approximated the tumor volume (V) by V = 4pR 3 / 3, where R, the radius of the sphere, is equal to D / 2. Consecutively,
To report the TGR results in a clinically meaningful way, they expressed TGR as a percentage increase in tumor volume using the following transformation, in which exp(TG) represents the exponent of TG: TGR = 100 exp(TG) À 1.
Our modified calculation of TGV
We aimed at the time-point of progression, and wanted to compare TGV before and after disease progression, so we chose the following three time-points: t1, last imaging assessment time before progression and drug withdrawal; t2, imaging assessment time at progression and drug withdrawal; and t3, first image assessment (1 month washout period) after progression and drug withdrawal, shown in Figure 1 . We also defined S1, S2 and S3 as the accumulated maximum diameters of at most three largest target lesions in at most two organs at t1, t2 and t3, respectively. Then, TGV before drug withdrawal: TGV1 = 100(S2 À S1) / S1 / (t2 À t1), and TGV after drug withdrawal: TGV2 = 100(S3 À S2) / S2 / (t3 À t2). The unit of TGV is per month.
Statistical analysis
We carried out pairwise comparisons to test the variations of TGV before and after sorafenib withdrawal using Wilcoxon signed rank tests. The t-test was used to compare the difference between the traditional TGR and our modified TGV. One-way ANOVA test was applied to compare the mean TGV between clinical subgroups. PFS was defined as the time from first administration of sorafenib to the first documentation of disease progression or death from any cause, whichever occurred first. OS was calculated from the date of the first dose of sorafenib to the date of death or Hypothetical representation of TGV across specific periods of tumor progression. t1, last imaging assessment time before progression and drug withdrawal; t2, imaging assessment time at progression and drug withdrawal; t3, first image assessment after progression and drug withdrawal. S1, S2 and S3 as the accumulated maximum diameters of at most three largest target lesions in at most two organs at t1, t2 and t3, respectively. last follow up. SPP was the interval from the date of progression to the date of death or last follow up. The concordance index and the proportion of two variance explained (R) were computed to assess the prediction performance for survival (PFS, OS). The follow-up duration was calculated using the reversed Kaplan-Meier method. Continuous variables were reported as medians and interquartile ranges, and categorical data were presented as proportions. The Shapiro-Wilk test was used to test whether the data were normality distributed. The OS was estimated using the Kaplan-Meier method with Rothman 95% CI and compared across the groups using the log-rank test. To evaluate the prognostic value of the investigated parameters, we calculated the HRs and 95% CIs using the Cox proportional hazards model. All analyses were carried out using SPSS software (version 19.0; SPSS Inc., Chicago, IL, USA).
P-values <0.05 were considered significant in all tests. All P-values were two-sided.
Results
Clinical characteristics and survival outcomes of the cohorts
The clinical features, MSKCC risk score, PFS and OS of the 114 included patients are described in Table 1 . A total of 82 patients were men, and 32 were women, with a median age of 55 years (22-81 years). The median PFS was 9.3 months (95% CI 6.7-11.8 months). A total of 12 patients received everolimus, seven patients received axitinib, 11 patients were enrolled into clinical trials and the remaining 84 patients were treated by traditional Chinese medicine after disease progression. To the last follow-up time, 108 (94.7%) patients had Change of TGV before and after sorafenib withdrawal
Our modified TGV was consistent with the traditional TGR (t-test, P < 0.001; Fig. 2 ). TGV1 was 7.347 AE 4.040, and TGV2 was 11.647 AE 5.937, paired samples t-test, P < 0.001. Higher TGV1 correlated to MSKCC high-risk score (P = 0.022), and KPS <80 (P = 0.028). Clear cell carcinoma seemed to have a lower TGV than non-clear cell carcinoma, both in TGV1 (6.930 AE 4.163 vs 8.831 AE 3.221, P = 0.037) and TGV2 (11.107 AE 5.867 vs 13.569 AE 5.899, P = 0.067). TGV was also positively correlated to tumor nucleus grade, P < 0.001 in TGV1 and P = 0.015 in TGV2. Furthermore, patients with the different treatment response had a different level of TGV; those with PR had the lowest level of TGV1 (P < 0.001), whereas those with SD showed the lowest level of TGV2 (P < 0.001).
The above results are listed and shown in Table 2 and Figure 3 .
TGV1 is independently associated with OS of the patients
On the basis of univariate analysis for OS, listed in Table 1 , we found MSKCC risk score, KPS, histological subtype, tumor nucleus grade, previous nephrectomy, time from nephrectomy to sorafenib treatment, number of metastatic organs and TGV1 were statistically significant. Patients with a TGV1 <5.0 had longer PFS and OS than those with a TGV1 >5.0, 19.1 months vs 6.8 months for PFS, P < 0.001; and 32.2 months vs 14.8 months for OS, P < 0.001, shown in Figure 4 . We here chose 5.0 as the threshold for TGV1 before drug withdrawal, because it had the maximal log rank v 2 value and minimal P-value on TGV1 in the Kaplan-Meier study for OS. These significant clinical variables were further put into the multivariate Cox regression model analyses carried out by backward step-way. Table 3 shows that MSKCC risk score, histology subtype, best response and TGV1 were independent predictors for OS in patients with mRCC treated by sorafenib.
TGV1 is associated with SPP of the patients in univariate analysis
The median SPP of the whole cohort was 8.0 months (95% CI 6.9-9.2 months), and MSKCC risk score, KPS, histological subtype, previous nephrectomy, time from nephrectomy to TKI treatment and TGV1 were statistically correlated to SPP by univariate analysis, listed in Table 1 . Patients with a TGV1 <5.0 had longer SPP than those with a TGV1 >5.0, 9.5 months versus 7.7 months, P = 0.040, shown in Figure 4 . However, TGV1 failed to be an independent factor for SPP in the further multivariate Cox regression model analyses carried out by backward step-way. Instead, MSKCC risk score remained the only significant factor in multivariate analyses (HR 1.579, P = 0.024).
Discussion
The RECIST has been used to evaluate the response of solid tumors to drug therapies for >10 years. Nevertheless, simply using the absolute alteration in tumor size as the standard to evaluate the efficacy of a certain agent is obviously inadequate in reflecting the real inhibitive activity on tumors in the era of targeted therapy. For example, a tumor with a baseline maximum diameter of 4 cm grew slowly to 4.9 cm without tumor-associated symptoms after 3 years of VEGF-TKI treatment. According to RECIST, it has reached PD, but the enlargement in a unit of time was very limited. The most probable issue is that this VEGF-TKI agent is still pharmaceutically effective in suppressing the tumor. Then, if we withdraw this agent and switch to another drug, it is likely that the tumor might grow faster, leading to a rapid progression, and ultimately affect the patient's long-term survival. Based on this problem, we need novel criteria to determine tumor progression under VEGF-TKI treatment. Inspired by the PSA velocity in prostate cancer, we first introduced TGV to re-evaluate patients with mRCC accepting sorafenib treatment. 18, 19 We believe our modified TGV is consistent with the traditional TGR described by Fert e et al., but much easier to calculate and clinically practice by oncologists. 17 Similar to a simple risk stratification method in oropharyngeal cancer, 20 TGV appeared to be a better prognostic indicator for disease progression and survival. 21 The phenomenon of disease rebound after TKI withdrawal has been reported in lung cancer 22, 23 and kidney cancer, 17 whereas it was not so common as originally feared. 24, 25 We also compared TGV before and after drug withdrawal, and found the TGV before withdrawal was 7.347 AE 4.040, and increased to 11.647 AE 5.937 after withdrawal, P < 0.001. The growth of tumors indeed accelerates after sorafenib withdrawal, which might induce the deterioration of disease. Sorafenib is probably still active or partially active in suppressing the tumor at the time-point of withdrawal in some patients, and drug withdrawal will break the balance between tumor growth and drug inhibition, leading to the fast progression of RCC. Stopping sorafenib immediately might do harm to these patients. For this situation, treatment beyond progression could be an option; otherwise, combination regimen with another agent aimed at different molecular targets, inhibiting the tumor synergically, is proven to be a feasible option (especially in terms of safety) based on available data. For example, TKIs combined with PD-1 inhibitor (axitinib plus pembrolizumab or levantinib plus pembrolizumab) could achieve better results and tolerable side-effects in several phase II clinical trials. [26] [27] [28] The current study also showed the correlations between TGV to other clinical and pathological characteristics of mRCC patients, including MSKCC, KPS, histological subtype and tumor nucleus grade. Cases with high risk in MSKCC, non-clear subtype, and higher nucleus grade would have higher TGV and grow rapidly, causing a rapid progression after initiating sorafenib. Here, we chose 5.0 as the threshold for TGV1 before drug withdrawal, because it had the maximal log-rank v 2 value and minimal P-value on TGV1 in the Kaplan-Meier study for OS. The median OS for patients with TGV1 <5.0 reached 32.2 months, whereas just 14.8 months in those with TGV1. TGV1 5.0 can help us select those fast progression patients receiving sorafenib treatment and change to another effective therapeutic option as soon as possible. In contrast, it is not so urgent to change the regimen for patients with TGV1 <5.0, as the current VEGF-TKI might still inhibit the tumor, and they are expected to have longer OS with slowly growing tumors. We propose to add TGV 5.0 as a supplement to RECIST for evaluating PD, thus allowing some PD patients who were selected to switch regimen to remain in the SD group, and continue the original VEGF-TKI; whereas a few patients who have not reached PD by RECIST, but with very high TGV1 >5.0, should have their treatment altered earlier. This recommendation could be especially applicable in low-income countries where a limited number of active agents are available for mRCC patients.
The major limitations of the present study were the retrospective design and relatively small heterogeneous sample. The accuracy of TGV to reflect the TGR at a certain time-period will decrease if there were long intervals between individual radiological evaluations. Thus, we recommend 2-3 months or even smaller intervals between CT scans to obtain a more accurate TGV. Furthermore, our modified TGV requires further validation in large sampled studies, and the study agents can involve all VEGF-TKIs (such as axitinib, pazopanib, sunitinib, cabozantinib and lenvatinib) and other drugs with different targets, such as mTOR inhibitors, bevacizumab, PD-1/PD-L1 inhibitors and so on. The subject investigated should not be restricted to mRCC -all solid tumors can be included to verify our results. As recommended by the European Association of Urology, European Multidisciplinary Congress on Urological Cancers and National Comprehensive Cancer Network, sorafenib is indeed no longer the usual treatment of choice for the second-line setting of mRCC in 2018. 29 However, patients in the current study were treated between April 2006 and April 2011, when sorafenib was still the standard of care second-line treatment for mRCC. Furthermore, as the first approved TKI agent for mRCC, sorafenib has a common mechanism with other TKI drugs, thus we consider the present results are common sense in the era of targeted therapy.
Significantly faster tumor growth appeared if sorafenib was discontinued, as far as disease progression reached by RECIST. Sorafenib might still be effective after PD, and we with initial PD showed higher TGV1 and TGV2 than those with partial response or SD, both P < 0.001.
suggest that treatment with sorafenib should be maintained for as long as possible before TGV is >5.0, and tumor response should be observed synchronously. 
